Literature DB >> 10912670

Graft-versus-Host disease-like syndrome in malignant thymoma.

M H Wang1, J M Wong, C Y Wang.   

Abstract

Allogenic transfusion of immunocompetent T lymphocytes into an immunodeficient recipient is necessary for the development of graft-versus-host-disease (GVHD). The gastrointestinal tract is one of the most involved organs in human GVHD, and single-cell necrosis with apoptotic change and crypt abscess are characteristic histopathologic features. The thymus is important in immune regulation, and dysregulation of the immune system can be expected once its microenvironment is disrupted. We report the case of a 38-year-old woman with malignant thymoma without transplantation or transfusion history who initially presented with myasthenia gravis and clinically developed a GVHD-like syndrome with characteristic GVHD-like colitis on colonoscopy. We propose that disruption of the thymic microenvironment caused a dysregulated immune system and development of a GVHD-like syndrome.

Entities:  

Mesh:

Year:  2000        PMID: 10912670     DOI: 10.1080/003655200750023660

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  10 in total

Review 1.  What is Good's syndrome? Immunological abnormalities in patients with thymoma.

Authors:  P Kelleher; S A Misbah
Journal:  J Clin Pathol       Date:  2003-01       Impact factor: 3.411

2.  Diminished regulatory T cells in cutaneous lesions of thymoma-associated multi-organ autoimmunity: a newly described paraneoplastic autoimmune disorder with fatal clinical course.

Authors:  T Hanafusa; H Azukizawa; S Kitaba; H Murota; N Umegaki; M Terao; S Sano; T Nakagiri; M Okumura; I Katayama
Journal:  Clin Exp Immunol       Date:  2011-11       Impact factor: 4.330

Review 3.  Good's syndrome remains a mystery after 55 years: A systematic review of the scientific evidence.

Authors:  Theodoros Kelesidis; Otto Yang
Journal:  Clin Immunol       Date:  2010-02-10       Impact factor: 3.969

Review 4.  Chemotherapy improves thymoma-associated graft-versus-host-disease-like erythroderma.

Authors:  Tatsuya Nagano; Yoshikazu Kotani; Kazuyuki Kobayashi; Nanako Tomita; Kyosuke Nakata; Akihiro Sakashita; Yasuhiro Funada; Hiroshi Nagai; Tomoo Itoh; Yoshihiro Nishimura
Journal:  BMJ Case Rep       Date:  2011-05-10

5.  Multimodal immunotherapy ameliorates myasthenia gravis preceded by thymoma-associated multiorgan autoimmunity.

Authors:  Hiroo Kasahara; Kazuki Shimizu; Kouki Makioka; Takaaki Sano; Yoichi Ohtaki; Yoshio Ikeda
Journal:  Immunol Res       Date:  2022-03-14       Impact factor: 2.829

Review 6.  Thymoma-associated multiorgan autoimmunity with exclusive gastrointestinal tract involvement: case report and review of the literature.

Authors:  Tomas Slavik; Fritz M Potgieter; David Brittain
Journal:  Virchows Arch       Date:  2018-01-26       Impact factor: 4.064

7.  [A 55-year-old woman with thymoma and hypogammaglobulinemia (Good syndrome), ulcerative colitis, and cytomegalovirus infection].

Authors:  Alisan Kahraman; Michael Miller; Evelyn Maldonado-Lopez; Hideo A Baba; Ulrich Treichel; Guido Gerken
Journal:  Med Klin (Munich)       Date:  2009-02-26

8.  Graft-versus-host disease-like erythroderma: a manifestation of thymoma-associated multiorgan autoimmunity.

Authors:  Shay Warren; Kishwer Nehal; Christiane Querfeld; Richard Wong; James Huang; Melissa Pulitzer
Journal:  J Cutan Pathol       Date:  2015-10       Impact factor: 1.587

Review 9.  Remission of Thymoma on Steroid Therapy in a Patient With Atypical Thymoma-Associated Multiorgan Autoimmunity: A Case Report and Literature Review.

Authors:  Ewa Wrona; Sylwia Dębska-Szmich; Marta Pastuszka; Marcin Braun; Rafał Czyżykowski; Piotr Potemski
Journal:  Front Immunol       Date:  2021-04-29       Impact factor: 7.561

10.  Graft-versus-host-like colitis and malignant thymoma.

Authors:  Philip W Lowry; John D Myers; Alex Geller; David G Bostwick; Jonathan E Clain
Journal:  Dig Dis Sci       Date:  2002-09       Impact factor: 3.487

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.